Bio-Techne Fiscal Q2 Revenues Rise 20 Percent
In its second fiscal quarter, the firm reported Diagnostics and Genomics revenues of $64.5 million, up 23 percent year over year from $52.5 million.
Stay updated with breaking news from Protein Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In its second fiscal quarter, the firm reported Diagnostics and Genomics revenues of $64.5 million, up 23 percent year over year from $52.5 million.
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2021. Second Quarter...
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ended December 31, 2021. Second Quarter...
Bio-Techne Corporation (TECH) has posted Q2 FY22 deals of $269.3 million, up 20% Y/Y, beating the agreement of $266.57 million.
/PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today...